The final phase of polio eradication: New vaccines and complex choices

Journal of Infectious Diseases

Volumn 205, Issue 2, 2012, Pages 169-171

  Cochi, Stephen L ^a   Linkins, Robert W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

DEVELOPING COUNTRY; ENDEMIC DISEASE; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION CONTROL; NOTE; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 1; POLIOMYELITIS VIRUS 2; POLIOMYELITIS VIRUS 3; PRIORITY JOURNAL; SEROCONVERSION; VACCINE PRODUCTION; VIRUS TRANSMISSION;

ANTIBODIES, VIRAL; FEMALE; HUMANS; MALE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL;

EID: 84555195608     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir727     Document Type: Note

References (28)

1. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. In: Plotkin SA, Orenstein WA, Offit P, eds. Vaccines. 5th ed. Saunders Elsevier, 2008: 631-85.
2. WHO Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity or oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. J Infect Dis 1995; 171:1097-106.
3. El-Sayed N, El-Gamal Y, Abbassy A, et al. Monovalent type 1 oral polio vaccine in newborns. N Engl J Med 2008; 359:1655-65.
4. John TJ, Jain H, Ravishankar K, et al. Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials. Vaccine 2011; 29:5793-801.
5. Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, doubleblind, controlled trial. Lancet 2010; 376: 1682-8.
6. Waggie Z, Geldenhuys H, Sutter RW, et al. Randomized Trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa. J Infect Dis 2011; 205:228-36.
7. Caceres VM, Sutter RW. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis 2001; 33:531-41. (Pubitemid 32709587)
8. Domok I. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959-1982. Rev Infect Dis 1984; 6(Suppl 2): S413-18.
9. Schoub BD, Johnson S, McAnererney J, et al. Monovalent neonatal polio immunization-a strategy for the developing world. J Infect Dis 1988; 157:836-9. (Pubitemid 18093751)
10. World Health Organization. Conclusions and recommendations of the Ad Hoc Advisory Committee on Poliomyelitis Eradication, Geneva, 21-22 September 2004. Wkly Epidemiol Rec 2004; 79:401-7.
11. Grassly NC, Wenger J, Durrani S, et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 2007; 369:1356-62. (Pubitemid 46613904)
12. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-worldwide, July 2009-March 2011. MMWR Morb Mortal Wkly Rep 2011; 60:846-50.
13. Modlin JF. The bumpy road to polio eradication. N Engl J Med 2010; 362:2346-9.
14. World Health Organization. Conclusions and recommendations of the Ad Hoc Advisory Committee on Poliomyelitis Eradication, Geneva, 27-28 November 2007. Wkly Epidemiol Rec 2008; 83:25-36.
15. World Health Organization. Advisory Committee on Poliomyelitis Eradication: recommendations on the use of bivalent oral poliovirus vaccine types 1 and 3. Wkly Epidemiol Rec 2009; 84:289-90.
16. Cochi SL, Sutter RW, Kew OM, Pallansch MA, Dowdle WA. World Health Organization. In: Decision tree for stopping polio immunization. Presented at the Technical Consultation on the Global Eradication of Poliomyelitis, Geneva, 28-29 April. 1997.
17. Cochi SL, Sutter RW, Kew OM, Pallansch MA, Dowdle WA. Possible global strategies for stopping polio immunization and how they could be harmonized. Brown F, ed. Progress in polio eradication: vaccine strategies for the end game. Dev Biol. Vol 105. Basel: Karger, 2001; 153-8.
18. Centers for Disease Control and Prevention. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep 2001; 50:222-4.
19. Aylward B, Yamada T. The polio endgame. N Engl J Med 2011; 364:2273-5.
20. Bhutta Z. The last mile in global poliomyelitis eradication. Lancet 2011; 378:549-52.
21. The Global Polio Eradication Initiative. www. polioeradication.org. Accessed 10 November 2011.
22. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. J Infect Dis 1997; 175(Suppl 1):S215-27.
23. World Health Organization. Polio vaccines and polio immunization in the preeradication era: WHO position paper. Wkly Epidemiol Rec 2010; 85:213-28.
24. Aylward RB, Sutter RW, Heymann DL. OPV cessation-the final step to a "poliofree" world. Science 2005; 310:625-6. (Pubitemid 41528143)
25. World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication. Geneva: World Health Organization, 2011. Resolution WHA 61.1.
26. Liao G, Li R, Li C, et al. World Health Organization. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains (Sabin IPV): a phase-II randomized positive-controlled trial. J Infect Dis 2011; 205:237-43.
27. Cochi SL, Sutter RW, Kew OM, PallanschMA, Dowdle WA. Possible strategies for stopping polio immunization. Expanded Programme on Immunization, Global Programme for Vaccines and immunization. Global eradication of poliomyelitis: "Report of the Meeting on the Scientific Basis for Stopping Immunization Against Poliomyelitis", WHO/EPI/GEN/98.12, World Health Organization, Geneva, March 23-25, 1998.
28. Milstien J. Feasibility of a global IPV strategy and sequential removal of Sabin strains. Expanded Programme on Immunization, Global Programme for Vaccines and immunization. Global eradication of poliomyelitis: "Report of the Meeting on the Scientific Basis for Stopping Immunization Against Poliomyelitis", WHO/EPI/GEN/98.12,World Health Organization, Geneva, March 23-25, 1998.